Literature DB >> 19828610

Role of scavenger receptor class B type I in hepatitis C virus entry: kinetics and molecular determinants.

Maria Teresa Catanese1, Helenia Ansuini, Rita Graziani, Thierry Huby, Martine Moreau, Jonathan K Ball, Giacomo Paonessa, Charles M Rice, Riccardo Cortese, Alessandra Vitelli, Alfredo Nicosia.   

Abstract

Scavenger receptor class B type I (SR-BI) is an essential receptor for hepatitis C virus (HCV) and a cell surface high-density-lipoprotein (HDL) receptor. The mechanism of SR-BI-mediated HCV entry, however, is not clearly understood, and the specific protein determinants required for the recognition of the virus envelope are not known. HCV infection is strictly linked to lipoprotein metabolism, and HCV virions may initially interact with SR-BI through associated lipoproteins before subsequent direct interactions of the viral glycoproteins with SR-BI occur. The kinetics of inhibition of cell culture-derived HCV (HCVcc) infection with an anti-SR-BI monoclonal antibody imply that the recognition of SR-BI by HCV is an early event of the infection process. Swapping and single-substitution mutants between mouse and human SR-BI sequences showed reduced binding to the recombinant soluble E2 (sE2) envelope glycoprotein, thus suggesting that the SR-BI interaction with the HCV envelope is likely to involve species-specific protein elements. Most importantly, SR-BI mutants defective for sE2 binding, although retaining wild-type activity for receptor oligomerization and binding to the physiological ligand HDL, were impaired in their ability to fully restore HCVcc infectivity when transduced into an SR-BI-knocked-down Huh-7.5 cell line. These findings suggest a specific and direct role for the identified residues in binding HCV and mediating virus entry. Moreover, the observation that different regions of SR-BI are involved in HCV and HDL binding supports the hypothesis that new therapeutic strategies aimed at interfering with virus/SR-BI recognition are feasible.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19828610      PMCID: PMC2798406          DOI: 10.1128/JVI.02199-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  64 in total

1.  Scavenger receptor class B Type I (SR-BI) assembles into detergent-sensitive dimers and tetramers.

Authors:  Daisy Sahoo; Yolanda F Darlington; Diana Pop; David L Williams; Margery A Connelly
Journal:  Biochim Biophys Acta       Date:  2006-03-31

2.  Scavenger receptor class B, type I (SR-BI) homo-dimerizes via its C-terminal region: fluorescence resonance energy transfer analysis.

Authors:  Daisy Sahoo; Yinan Peng; Jeffery R Smith; Yolanda F Darlington; Margery A Connelly
Journal:  Biochim Biophys Acta       Date:  2007-05-18

3.  LDL particle subspecies are distinct in their capacity to mediate free cholesterol efflux via the SR-BI/Cla-1 receptor.

Authors:  Morgan Tréguier; Martine Moreau; Andrei Sposito; M John Chapman; Thierry Huby
Journal:  Biochim Biophys Acta       Date:  2006-12-20

Review 4.  Mechanism of action of interferon and ribavirin in treatment of hepatitis C.

Authors:  Jordan J Feld; Jay H Hoofnagle
Journal:  Nature       Date:  2005-08-18       Impact factor: 49.962

5.  Scavenger receptor class B type I is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81.

Authors:  Mirjam B Zeisel; George Koutsoudakis; Eva K Schnober; Anita Haberstroh; Hubert E Blum; François-Loïc Cosset; Takaji Wakita; Daniel Jaeck; Michel Doffoel; Cathy Royer; Eric Soulier; Evelyne Schvoerer; Catherine Schuster; Françoise Stoll-Keller; Ralf Bartenschlager; Thomas Pietschmann; Heidi Barth; Thomas F Baumert
Journal:  Hepatology       Date:  2007-12       Impact factor: 17.425

Review 6.  Epidemiology of hepatitis C virus infection.

Authors:  Miriam J Alter
Journal:  World J Gastroenterol       Date:  2007-05-07       Impact factor: 5.742

7.  High-avidity monoclonal antibodies against the human scavenger class B type I receptor efficiently block hepatitis C virus infection in the presence of high-density lipoprotein.

Authors:  Maria Teresa Catanese; Rita Graziani; Thomas von Hahn; Martine Moreau; Thierry Huby; Giacomo Paonessa; Claudia Santini; Alessandra Luzzago; Charles M Rice; Riccardo Cortese; Alessandra Vitelli; Alfredo Nicosia
Journal:  J Virol       Date:  2007-05-16       Impact factor: 5.103

8.  Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry.

Authors:  Matthew J Evans; Thomas von Hahn; Donna M Tscherne; Andrew J Syder; Maryline Panis; Benno Wölk; Theodora Hatziioannou; Jane A McKeating; Paul D Bieniasz; Charles M Rice
Journal:  Nature       Date:  2007-02-25       Impact factor: 49.962

9.  Scavenger receptor BI and BII expression levels modulate hepatitis C virus infectivity.

Authors:  Joe Grove; Thierry Huby; Zania Stamataki; Thomas Vanwolleghem; Philip Meuleman; Michelle Farquhar; Anne Schwarz; Martine Moreau; James S Owen; Geert Leroux-Roels; Peter Balfe; Jane A McKeating
Journal:  J Virol       Date:  2007-01-10       Impact factor: 5.103

10.  Diverse CD81 proteins support hepatitis C virus infection.

Authors:  Mike Flint; Thomas von Hahn; Jie Zhang; Michelle Farquhar; Christopher T Jones; Peter Balfe; Charles M Rice; Jane A McKeating
Journal:  J Virol       Date:  2006-08-30       Impact factor: 5.103

View more
  66 in total

1.  Impact of intra- and interspecies variation of occludin on its function as coreceptor for authentic hepatitis C virus particles.

Authors:  Sandra Ciesek; Sandra Westhaus; Melanie Wicht; Ilka Wappler; Sylvana Henschen; Christoph Sarrazin; Nabila Hamdi; Ahmed I Abdelaziz; Christian P Strassburg; Heiner Wedemeyer; Michael P Manns; Thomas Pietschmann; Thomas von Hahn
Journal:  J Virol       Date:  2011-06-01       Impact factor: 5.103

2.  A human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo.

Authors:  Philip Meuleman; Maria Teresa Catanese; Lieven Verhoye; Isabelle Desombere; Ali Farhoudi; Christopher T Jones; Timothy Sheahan; Katarzyna Grzyb; Riccardo Cortese; Charles M Rice; Geert Leroux-Roels; Alfredo Nicosia
Journal:  Hepatology       Date:  2011-12-16       Impact factor: 17.425

3.  Evaluation of ITX 5061, a scavenger receptor B1 antagonist: resistance selection and activity in combination with other hepatitis C virus antivirals.

Authors:  Haihong Zhu; Flossie Wong-Staal; Haekyung Lee; Andrew Syder; Jeffrey McKelvy; Robert T Schooley; David L Wyles
Journal:  J Infect Dis       Date:  2012-02-15       Impact factor: 5.226

Review 4.  Adaptive immunity to the hepatitis C virus.

Authors:  Christopher M Walker
Journal:  Adv Virus Res       Date:  2010       Impact factor: 9.937

5.  Mouse-specific residues of claudin-1 limit hepatitis C virus genotype 2a infection in a human hepatocyte cell line.

Authors:  Sibylle Haid; Marc P Windisch; Ralf Bartenschlager; Thomas Pietschmann
Journal:  J Virol       Date:  2009-11-04       Impact factor: 5.103

Review 6.  Unexpected structural features of the hepatitis C virus envelope protein 2 ectodomain.

Authors:  Ali Sabahi; Susan L Uprichard; William C Wimley; Srikanta Dash; Robert F Garry
Journal:  J Virol       Date:  2014-07-02       Impact factor: 5.103

Review 7.  Hepatitis C virus host cell entry.

Authors:  Alexander Ploss; Matthew J Evans
Journal:  Curr Opin Virol       Date:  2012-01-04       Impact factor: 7.090

8.  Hepatitis C virus is primed by CD81 protein for low pH-dependent fusion.

Authors:  Nishi R Sharma; Guaniri Mateu; Marlene Dreux; Arash Grakoui; François-Loïc Cosset; Gregory B Melikyan
Journal:  J Biol Chem       Date:  2011-07-07       Impact factor: 5.157

9.  Adaptation of hepatitis C virus to mouse CD81 permits infection of mouse cells in the absence of human entry factors.

Authors:  Julia Bitzegeio; Dorothea Bankwitz; Kathrin Hueging; Sibylle Haid; Christiane Brohm; Mirjam B Zeisel; Eva Herrmann; Marcus Iken; Michael Ott; Thomas F Baumert; Thomas Pietschmann
Journal:  PLoS Pathog       Date:  2010-07-01       Impact factor: 6.823

10.  A novel small molecule inhibitor of hepatitis C virus entry.

Authors:  Carl J Baldick; Michael J Wichroski; Annapurna Pendri; Ann W Walsh; Jie Fang; Charles E Mazzucco; Kevin A Pokornowski; Ronald E Rose; Betsy J Eggers; Mayla Hsu; Weixu Zhai; Guangzhi Zhai; Samuel W Gerritz; Michael A Poss; Nicholas A Meanwell; Mark I Cockett; Daniel J Tenney
Journal:  PLoS Pathog       Date:  2010-09-02       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.